MIRA Pharmaceuticals Announces Virtual Annual Meeting to Discuss SKNY Merger

New activity is brewing for MIRA Pharmaceuticals, Inc. ( (MIRA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.

MIRA Pharmaceuticals, Inc. has announced a virtual annual meeting of stockholders scheduled for September 11, 2025, to discuss several key proposals, including the approval of a merger with SKNY Pharmaceuticals, Inc. The merger aims to create a biopharmaceutical company with a diverse portfolio of product candidates. The merger, agreed upon on June 16, 2025, will result in a company where pre-merger equity holders of both MIRA and SKNY will each hold approximately 50% of the outstanding shares. This strategic move is expected to enhance MIRA’s market positioning by expanding its therapeutic offerings and potentially increasing its market share.

The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development and potential commercialization of novel, potentially first-in-class product candidates targeting therapeutic areas such as smoking cessation, obesity, pain management, depression, PTSD, and cognitive impairment.

Average Trading Volume: 1,353,821

Technical Sentiment Signal: Strong Buy

For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.